Belite Bio Inc.

02/01/2023 | Press release | Distributed by Public on 02/01/2023 01:15

Belite Bio Submits IND Amendment to Initiate Phase 3 Clinical Trial of Tinlarebant (LBS-008) in Advanced Dry AMD